Fig. 1From: External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular diseaseFlowchart of the process of applying the in- and exclusion criteria of cardiovascular outcome trials to UCC-SMART type 2 diabetes patients with cardiovascular diseaseBack to article page